[口試公告] 113-2碩士學位論文口試
| 學生姓名 | 口試時間 | 論文題目 |
| 趙苡雯 CHAO, YI-WEN |
2025/06/30 | 荷爾蒙療法對於乳癌病人心血管代謝結果的比較：以全國人口為對象之研究 Comparative Analysis of Cardiometabolic Outcomes in Breast Cancer Patients Receiving Endocrine Therapy: A Nationwide Population-Based Cohort Study |
| 謝心瑜 HSIEH, HSIN-YU |
2025/06/27 | 評估接受經皮冠狀動脈介入治療的心房顫動病人使用抗血栓藥物的療效與安全性 Evaluating the Effectiveness and Safety of Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention |
| 李怡欣 LEE, YI-SIN |
2025/06/26 | Isavuconazole 與 Voriconazole 用於侵襲性麴菌病先發性及確認性治療之 42 天住院死亡率比較：單中心回溯性世代研究 Comparison of 42-Day In-Hospital Mortality Between Isavuconazole and Voriconazole for Preemptive and Definitive Treatment of Invasive Aspergillosis: A Single-Center Retrospective Cohort Study |
| 林佩璉 LIN, PEI-LIEN |
2025/06/12 | 台灣BRCA基因突變型轉移型去勢抗性前列腺癌病人使用第一線療法 PARP 抑制劑 Olaparib 或 Niraparib 合併 Abiraterone 或單用 Abiraterone 之成本效果分析 Cost-Effectiveness Analysis of Olaparib and Niraparib With Abiraterone Versus Abiraterone for First-Line Treatment of BRCA Mutated Metastatic Castration-Resistant Prostate Cancer in Taiwan |
| 孟欣妤 MENG, HSIN-YU |
2025/05/29 | 台灣EGFR突變非小細胞肺癌病人使用第一線療法 Amivantamab 合併 Lazertinib 或 Osimertinib 之成本效果分析
Cost-Effectiveness Analysis of Amivantamab with Lazertinib Versus Osimertinib as First-Line Therapy for EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (NSCLC) in Taiwan |
| 蔡小童 TSAI, HSIAO-TUNG |
2025/05/29 | 臺灣第II到IIIA期PD-L1表現≥ 1%且不適用標靶治療之可切除非小細胞肺癌病人使用免疫檢查點抑制劑Atezolizumab或Pembrolizumab輔助性治療之成本效果分析 Cost-effectiveness Analysis of Adjuvant Atezolizumab or Pembrolizumab in Resectable Stage II–IIIA Non–Small Cell Lung Cancer Patients with PD-L1 ≥1% Expression and Ineligible for TKI Therapy in Taiwan |
~ 2025/6/10更新